UB Paderborn / Katalog / Suche / in CDI

Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2004-09, Vol.48 (9), p.3233-3240

2004

Volltextzugriff (PDF)

Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins

Innate immunity (London, England), 2012-02, Vol.18 (1), p.171-178

2012

Volltextzugriff (PDF)

Experimental Human Endotoxemia Is Associated With Depression of Load-Independent Contractility Indices

Chest, 2004-09, Vol.126 (3), p.860-867

2004

Volltextzugriff (PDF)

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis

Critical care medicine, 2010-01, Vol.38 (1), p.72-83

2010

Volltextzugriff (PDF)

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]

The Journal of pharmacology and experimental therapeutics, 2004-01, Vol.308 (1), p.175

2004

Volltextzugriff (PDF)

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Antimicrobial Agents and Chemotherapy, 2003-09, Vol.47 (9), p.2796-2803

2003

Volltextzugriff (PDF)

Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

Antimicrobial Agents and Chemotherapy, 2000-03, Vol.44 (3), p.504-510

2000

Volltextzugriff (PDF)

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

Shock (Augusta, Ga.), 2011-10, Vol.36 (4), p.327-331

2011

Volltextzugriff (PDF)

Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels

Antimicrobial Agents and Chemotherapy, 1999-10, Vol.43 (10), p.2562-2564

1999

Volltextzugriff (PDF)

Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia

The Journal of infectious diseases, 2003-02, Vol.187 (4), p.631-639

2003

Volltextzugriff (PDF)

TLR4 antagonists for endotoxemia and beyond

Current opinion in investigational drugs (London, England : 2000), 2005-05, Vol.6 (5), p.496

2005

Volltextzugriff (PDF)

Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid A analogue E5531

Chest, 2004-09, Vol.126 (3), p.860-867

2004

Volltextzugriff (PDF)

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

Innate immunity (London, England), 2008-12, Vol.14 (6), p.383-394

2008

Volltextzugriff (PDF)

Elevated Plasma Levels of Limulus Amoebocyte Lysate–Reactive Material

The Journal of infectious diseases, 2006-11, Vol.194 (9), p.1340-1340

2006

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid A Antagonist, during an Ascending Single-Dose Clinical Study

Journal of clinical pharmacology, 2003-07, Vol.43 (7), p.735-742

2003

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men

Innate immunity (London, England), 2012-12, Vol.18 (6), p.793-803

2012

Volltextzugriff (PDF)

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

Pharmaceutical research, 2008, Vol.25 (1), p.176-182

2008

Volltextzugriff (PDF)

A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia

Critical care medicine, 2000-08, Vol.28 (8), p.2713-2720

2000

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid a Antagonist, during an Ascending Single-Dose Clinical Study

Journal of clinical pharmacology, 2003-07, Vol.43 (7), p.735-742

2003

Volltextzugriff (PDF)

EFFECT OF E5531 ON SYSTEMIC RESPONSES TO ENDOTOXIN IN HEALTHY VOLUNTEERS

Critical care medicine, 1995-01, Vol.23 (Supplement), p.A147

1995

Volltextzugriff (PDF)

E5531, AN ENDOTOXIN ANTAGONIST, BLOCKS THE HYPERDYNAMIC AND DEPRESSANT CARDIOVASCULAR EFFECTS OF ENDOTOXIN IN HEALTHY SUBJECTS

Critical care medicine, 1995-01, Vol.23 (Supplement), p.A151

1995

Volltextzugriff (PDF)

IMMUNOPROTECTIVE ACTIVITY OF RIBOSOMES FROM HEMOPHILUS INFLUENZAE TYPE B

LYNN, MELVYN

1975

Volltextzugriff (PDF)

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

Journal of endotoxin research, 2002-12, Vol.8 (6), p.483

2002

Volltextzugriff (PDF)

CONTRIBUTION TO THA-THEORY OF THE NUMERICAL SOLUTION OF SETS OF LINEAR EQUATIONS

LYNN, MELVYN STUART

1962

Volltextzugriff (PDF)

EFFECT OF E5531 ON SYSTEMIC RESPONSES TO ENDOTOXIN IN HEALTHY VOLUNTEERS

Critical care medicine, 1995-01, Vol.23 (1 Suppl), p.A147-A147

1995

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins

Experimental Human Endotoxemia Is Associated With Depression of Load-Independent Contractility Indices

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels

Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia

TLR4 antagonists for endotoxemia and beyond

Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid A analogue E5531

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

Elevated Plasma Levels of Limulus Amoebocyte Lysate–Reactive Material

Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid A Antagonist, during an Ascending Single-Dose Clinical Study

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia

Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid a Antagonist, during an Ascending Single-Dose Clinical Study

EFFECT OF E5531 ON SYSTEMIC RESPONSES TO ENDOTOXIN IN HEALTHY VOLUNTEERS

E5531, AN ENDOTOXIN ANTAGONIST, BLOCKS THE HYPERDYNAMIC AND DEPRESSANT CARDIOVASCULAR EFFECTS OF ENDOTOXIN IN HEALTHY SUBJECTS

IMMUNOPROTECTIVE ACTIVITY OF RIBOSOMES FROM HEMOPHILUS INFLUENZAE TYPE B

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

CONTRIBUTION TO THA-THEORY OF THE NUMERICAL SOLUTION OF SETS OF LINEAR EQUATIONS

EFFECT OF E5531 ON SYSTEMIC RESPONSES TO ENDOTOXIN IN HEALTHY VOLUNTEERS

Suchergebnisse filtern